Biochemical recurrence means prostate-specific antigen (PSA) has risen after treatment intended to control or cure prostate cancer, suggesting recurrent cancer before recurrence is necessarily visible on imaging or causing symptoms. It is also called biochemical relapse or PSA recurrence. The definition depends on the original treatment: after radical prostatectomy PSA should become undetectable, whereas after radiation the prostate remains and PSA can remain measurable. For that reason, the PSA threshold used after surgery is not the same threshold used after radiation.
Biochemical recurrence (BCR) is a PSA-defined sign that prostate cancer may have returned after definitive local treatment, without requiring a visible tumor, metastasis or symptoms. After radical prostatectomy, the AUA defines BCR as PSA ≥0.2 ng/mL with a confirmatory value >0.2 ng/mL; however, current EAU guidance emphasizes that any confirmed rising PSA after prostatectomy can signal recurrence and that no single threshold perfectly separates harmless PSA detectability from clinically meaningful relapse. After radiation therapy, the standard Phoenix definition is PSA nadir + 2.0 ng/mL. A single tiny PSA rise does not automatically mean treatment has failed: repeat testing, PSA kinetics, pathology, treatment history and—when it will alter management—modern imaging determine what happens next.
01What Is Biochemical Recurrence?
Biochemical recurrence is a laboratory signal—not necessarily visible disease
NCI defines biochemical recurrence as a rise in PSA after prostate cancer treatment with surgery or radiation.
The important boundary is:
BCR can exist even when the patient feels well and imaging does not yet show a recurrent tumor.
That is why BCR is often called:
- biochemical relapse;
- PSA recurrence;
- or PSA failure.
Does biochemical recurrence mean the cancer has definitely spread?
No.
A PSA rise can reflect recurrent prostate cancer, but BCR by itself does not tell clinicians:
- whether disease is confined to the prostate bed;
- whether pelvic lymph nodes contain disease;
- whether distant metastases exist;
- or how quickly recurrence will become clinically important.
The same PSA-defined state can therefore represent very different biological situations.
Why does PSA usually detect recurrence before symptoms?
Prostate adenocarcinoma often continues to produce PSA even when recurrent tumor volume is too small to:
- cause pain;
- cause urinary obstruction;
- create a palpable mass;
- or be visible on standard imaging.
EAU notes that PSA recurrence almost always precedes clinical recurrence after local treatment.
Does every detectable PSA require immediate treatment?
No.
Current EAU follow-up guidance explicitly distinguishes:
a detectable PSA indicating relapse from a clinically meaningful relapse.
Factors that determine clinical significance include:
- the treatment used;
- PSA level;
- whether PSA is repeatedly rising;
- PSA doubling time;
- pathological Grade Group;
- pathological or clinical stage;
- time from treatment to recurrence;
- imaging findings;
- life expectancy;
- and whether potentially curative salvage treatment is feasible.
Why are the definitions different after surgery and radiation?
Because the treatments leave different amounts of PSA-producing tissue behind.
After radical prostatectomy:
- the prostate is removed;
- PSA is expected to become undetectable;
- therefore even a low confirmed rise can be clinically relevant.
After radiation:
- the prostate remains inside the body;
- benign prostate cells can continue producing PSA;
- PSA often falls slowly rather than immediately;
- so recurrence is defined relative to the lowest post-treatment PSA—the nadir.
Definition rule: biochemical recurrence is not a synonym for metastatic prostate cancer. It identifies a PSA-defined recurrence signal; subsequent risk assessment and imaging determine whether recurrent disease is local, regional, distant—or not yet visible.
02How Is Biochemical Recurrence Defined After Radical Prostatectomy?
PSA is expected to become undetectable after the prostate is removed
Current EAU follow-up guidance states that PSA is expected to be undetectable approximately two months after radical prostatectomy.
The exact assay matters because modern ultrasensitive tests can measure extremely small PSA concentrations that older tests could not detect.
What is the AUA definition after prostatectomy?
The 2024 AUA/ASTRO/SUO Salvage Therapy guideline defines post-prostatectomy biochemical recurrence as:
PSA ≥0.2 ng/mL followed by a confirmatory PSA >0.2 ng/mL.
This remains an important standardized definition for clinical practice and research.
Does EAU use exactly the same threshold?
Not exactly.
Current EAU follow-up language states that:
- PSA should become undetectable after prostatectomy;
- a rising PSA is considered a recurrence signal;
- but no definitive post-prostatectomy PSA threshold can perfectly define relapse for every patient.
EAU also notes that a PSA level above 0.4 ng/mL best predicts subsequent metastases in available evidence, which is a different question from the earliest biochemical definition.
Why can both statements be true?
Because there are two related but different questions:
- When should we label PSA recurrence consistently? AUA uses the confirmed ≥0.2 ng/mL definition.
- At what PSA level does recurrence become more strongly associated with later metastasis? EAU cites evidence favoring >0.4 ng/mL for that prognostic purpose.
Neither means clinicians should deliberately wait until PSA reaches 0.4 before discussing salvage therapy.
What if PSA is detectable but below 0.2 ng/mL?
This is where ultrasensitive PSA can create both opportunity and anxiety.
The AUA guideline says clinicians may use ultrasensitive PSA in patients at high recurrence risk when early salvage radiation would be considered.
But if the patient:
- does not yet meet the AUA BCR threshold;
- and has only a low detectable ultrasensitive PSA;
AUA recommends confirming a rising trend before proceeding with therapy.
Why not treat one ultrasensitive PSA result?
Because a tiny detectable value can represent:
- assay variation;
- minute benign residual prostate tissue;
- a stable low-level PSA;
- or the earliest phase of true recurrent cancer.
A trend across repeated measurements is therefore more informative than one isolated value.
What is persistent PSA after prostatectomy?
Persistent PSA is related to—but not identical to—classic biochemical recurrence.
In classic BCR:
- PSA becomes undetectable after surgery;
- then rises later.
With persistent PSA:
- PSA never becomes adequately undetectable after surgery.
Persistent PSA can reflect:
- residual local prostate cancer;
- lymph-node disease;
- distant micrometastatic disease;
- or less commonly benign residual prostate tissue.
EAU evidence associates persistent PSA with worse oncological outcomes overall, although not every patient with a low persistent PSA progresses.
Is biochemical recurrence after prostatectomy automatically treated?
No.
Treatment depends on:
- PSA kinetics;
- pathological Grade Group;
- pathological stage;
- margin status;
- node status;
- time to recurrence;
- imaging;
- life expectancy;
- prior treatment toxicity;
- and patient preferences.
Do not confuse a standardized BCR definition with a treatment trigger. The AUA ≥0.2 ng/mL confirmed threshold standardizes recurrence, but modern salvage radiation can be considered at lower PSA in selected high-risk patients because outcomes are generally better when salvage treatment is delivered early.
03How Is Biochemical Recurrence Defined After Radiation Therapy?
PSA behaves differently because the prostate remains in place
After external-beam radiation or brachytherapy:
- the prostate gland remains;
- benign prostate tissue can continue producing PSA;
- PSA usually falls gradually rather than disappearing;
- and the lowest value may not occur for years.
EAU notes that the time to PSA nadir after radiation can be up to three years or more.
What is the Phoenix definition?
The standard definition of biochemical failure after definitive radiation is:
PSA rise of 2.0 ng/mL above the post-treatment PSA nadir.
For example:
- if the nadir is 0.4 ng/mL, Phoenix biochemical recurrence occurs at 2.4 ng/mL;
- if the nadir is 1.1 ng/mL, the threshold is 3.1 ng/mL.
This definition also applies when radiation was combined with ADT.
Does PSA need to reach zero after radiation?
No.
Expecting an undetectable PSA after radiation applies a post-prostatectomy model to the wrong treatment.
A measurable PSA can be entirely compatible with successful radiation treatment.
What is a PSA bounce?
NCI defines PSA bounce as:
a temporary PSA rise followed by a fall, occurring in some patients about 1–3 years after prostate radiation.
A PSA bounce does not mean the cancer has returned.
Why does PSA bounce matter?
Because a temporary rise can create unnecessary fear or premature salvage treatment if clinicians interpret every increase as recurrence.
Bounce is particularly recognized after:
- brachytherapy;
- and some external-beam regimens.
The pattern matters:
- a bounce rises and subsequently falls;
- true biochemical recurrence tends to establish a persistent rising trajectory and ultimately meet or exceed the Phoenix threshold.
Can recurrence be investigated before PSA reaches nadir + 2?
Yes—in selected situations.
The Phoenix definition is a standardized definition of biochemical failure, not a rule forbidding earlier evaluation.
Modern PSMA PET can detect recurrence at PSA levels below the historical Phoenix threshold in some patients.
Earlier evaluation can be reasonable when:
- PSA is rising rapidly;
- the patient is a potential candidate for curative salvage treatment;
- there are high-risk pathological features;
- or imaging results would change treatment planning.
Why might prostate MRI be used after radiation?
EAU recommends prostate MRI to localize suspicious areas and guide biopsy in patients who are fit for local salvage treatment after radiotherapy.
That matters because local salvage treatments after prior radiation:
- carry meaningful urinary, sexual and rectal toxicity;
- and should generally be reserved for highly selected patients with confirmed local recurrence.
Radiation rule: do not label recurrence from one modest PSA rise. Interpret PSA relative to the nadir, allow for benign bounce, examine the trajectory and use modern imaging earlier only when the result can meaningfully change salvage management.
04What Makes Biochemical Recurrence Higher or Lower Risk?
PSA level alone is not enough
Two patients can both meet the biochemical-recurrence definition and still have very different probabilities of:
- metastatic progression;
- prostate-cancer-specific death;
- or remaining free of clinically significant disease for many years.
Risk stratification therefore asks:
How aggressive was the original cancer, and how quickly is the recurrence declaring itself?
What is PSA doubling time?
PSA doubling time (PSA-DT) estimates how long it takes PSA to double.
A shorter doubling time generally indicates:
- faster tumor growth;
- greater risk of metastatic progression;
- and a stronger reason to consider active salvage or systemic treatment.
PSA-DT should be calculated from multiple measurements rather than guessed from two values taken very close together.
How does EAU classify BCR after prostatectomy?
The current EAU system divides post-prostatectomy BCR into two broad risk groups.
EAU low-risk BCR after RP:
- PSA-DT > 1 year;
- and pathological ISUP Grade Group < 4.
EAU high-risk BCR after RP:
- PSA-DT ≤ 1 year;
- or pathological ISUP Grade Group 4–5.
How does EAU classify BCR after radiation?
EAU low-risk BCR after RT:
- interval to biochemical failure > 18 months;
- and biopsy ISUP Grade Group < 4.
EAU high-risk BCR after RT:
- interval to biochemical failure ≤ 18 months;
- or biopsy ISUP Grade Group 4–5.
What additional high-risk features does AUA emphasize after prostatectomy?
AUA/ASTRO/SUO highlights features such as:
- Grade Group 4–5;
- pathological stage pT3b–pT4;
- node-positive disease;
- short PSA doubling time;
- short interval from treatment to recurrence;
- higher post-prostatectomy PSA;
- validated genomic classifier risk;
- and PET imaging findings.
Surgical margins are also relevant, but interpretation is nuanced: positive margins increase the probability of BCR while sometimes also suggesting a local prostate-bed source that can be more amenable to salvage radiation.
Why does time to recurrence matter?
A recurrence appearing very soon after definitive treatment is generally more concerning than one emerging after many years.
Longer intervals can indicate:
- slower tumor biology;
- lower metastatic potential;
- and a longer time horizon before recurrence becomes clinically significant.
But long-latency BCR still requires risk assessment rather than automatic dismissal.
Risk rule: PSA kinetics often matter more than one isolated PSA number. A slowly rising PSA years after treatment in lower-grade disease is biologically different from a rapidly doubling PSA soon after treatment in Grade Group 4–5 disease.
05What Happens After a PSA Rise Suggests Biochemical Recurrence?
Step 1: confirm the PSA pattern
NCI advises that one elevated post-treatment PSA does not always mean prostate cancer has returned.
The first step is often:
- repeat PSA;
- confirm the direction of change;
- review which assay was used;
- and compare with prior values.
After surgery, this is particularly important for ultrasensitive PSA below the standardized BCR threshold.
Step 2: identify the original treatment
Ask:
- Was the prostate removed?
- Was the prostate irradiated?
- Was brachytherapy used?
- Was ADT given and when did it stop?
Without that context, a PSA number cannot be interpreted correctly.
Step 3: calculate recurrence risk
Relevant variables include:
- PSA doubling time;
- Grade Group;
- pathological or clinical stage;
- margin status after surgery;
- node status;
- interval from treatment to PSA recurrence;
- current PSA;
- and overall health/life expectancy.
Step 4: decide whether imaging will change management
EAU recommends imaging at recurrence only when the result will affect treatment planning.
Current EAU guidance recommends:
- after prostatectomy: PSMA PET/CT when PSA is >0.2 ng/mL if the result will influence subsequent treatment;
- after radiotherapy: PSMA PET/CT in patients fit for curative salvage treatment;
- after radiotherapy: prostate MRI to localize suspicious intraprostatic areas and guide biopsy when local salvage is being considered.
What can PSMA PET show?
PSMA PET can identify:
- local recurrence in the prostate bed;
- pelvic lymph-node recurrence;
- distant lymph-node disease;
- bone metastases;
- and some visceral metastases.
But its sensitivity falls at very low PSA levels.
AUA evidence summarizes detection rates that increase as PSA rises, with substantially lower detection below 0.5 ng/mL than at higher PSA values.
Does a negative PSMA PET mean there is no recurrence?
No.
Microscopic recurrent cancer can remain below PET resolution.
The AUA/ASTRO/SUO salvage guideline specifically advises clinicians not to withhold salvage prostate-bed radiation solely because PSMA PET/CT is negative in a patient with post-prostatectomy BCR.
When is salvage radiation considered after prostatectomy?
For a patient with a detectable PSA after prostatectomy in whom salvage radiation is being considered, AUA/ASTRO/SUO recommends providing salvage radiation when PSA is:
≤0.5 ng/mL.
For selected patients at high risk of clinical progression, salvage radiation may be offered at:
PSA <0.2 ng/mL.
This is why the standardized ≥0.2 BCR definition should not be misread as a rule requiring clinicians to wait until PSA reaches that value in every high-risk patient.
Does everyone with BCR after prostatectomy need salvage radiation?
No.
EAU recommends monitoring as a reasonable option for some EAU low-risk BCR patients.
The balance includes:
- probability of progression;
- probability of cure with salvage treatment;
- urinary continence;
- erectile function;
- bowel toxicity;
- age/comorbidity;
- and patient priorities.
What happens after BCR following radiation?
The decision is more complex because the prostate has already received a curative radiation dose.
In highly selected patients with biopsy-proven local recurrence, EAU lists salvage approaches such as:
- salvage radical prostatectomy;
- salvage brachytherapy;
- stereotactic re-irradiation in experienced centers;
- high-intensity focused ultrasound in selected research/experienced settings;
- or cryoablation in selected research/experienced settings.
These procedures can carry substantial urinary, rectal and sexual morbidity, so confirming disease location matters.
When is systemic treatment considered?
Systemic treatment depends on:
- PSA doubling time;
- imaging findings;
- prior therapy;
- symptoms;
- and whether local salvage can reasonably control disease.
EAU 2026 specifically advises against routine ADT for non-metastatic BCR when PSA-DT is >12 months.
For higher-risk non-metastatic BCR resembling the EMBARK population, EAU recommends enzalutamide with ADT when PSA-DT is ≤9 months.
This page stops at the definition and immediate decision framework. The next guide, Recurrent Prostate Cancer, should own the broader local, regional and metastatic recurrence pathways.
→Biochemical Recurrence Definitions and Next-Step Meaning
| Clinical situation | PSA interpretation | What it means | Typical next question |
|---|---|---|---|
| After RP: undetectable PSA | Expected post-treatment state. | No biochemical evidence of recurrence. | Continue PSA surveillance. |
| After RP: low ultrasensitive detectable PSA <0.2 | Not automatically AUA-defined BCR. | Could be early recurrence, stable low PSA or assay/residual-tissue signal. | Is there a confirmed rising trend, and is the patient high risk enough for very early salvage evaluation? |
| After RP: PSA ≥0.2 + confirmatory >0.2 | Meets AUA BCR definition. | PSA-defined recurrence. | What is PSA-DT, pathological risk and salvage-RT candidacy? |
| After RP: PSA never becomes undetectable | Persistent PSA. | Different from classic delayed BCR and may indicate residual disease. | Where is disease likely located and how high risk is the PSA trajectory? |
| After RT: measurable but falling/stable PSA | Expected; prostate remains. | Not recurrence simply because PSA is detectable. | Has PSA reached a nadir, and is the trend stable? |
| After RT: temporary rise then fall | Possible PSA bounce. | Can be benign, especially 1–3 years post-radiation. | Does repeat PSA fall again? |
| After RT: nadir + 2.0 ng/mL | Meets Phoenix BCR definition. | Standardized biochemical failure after radiation. | Is recurrence local, nodal or distant, and is curative salvage realistic? |
| Any BCR + fast PSA-DT/high grade | Higher-risk biochemical recurrence. | Greater risk of clinical/metastatic progression. | Does imaging alter local salvage or systemic-treatment planning? |
Key Points
- Biochemical recurrence is a PSA rise after prostate cancer treatment that suggests recurrent disease before recurrence is necessarily visible or symptomatic.
- Biochemical recurrence, biochemical relapse and PSA recurrence are commonly used for the same PSA-defined state.
- BCR does not automatically mean metastatic prostate cancer.
- The recurrence definition depends on whether the original treatment was prostatectomy or radiation.
- After radical prostatectomy, PSA is expected to become undetectable by roughly two months.
- The AUA defines post-prostatectomy BCR as PSA ≥0.2 ng/mL with a confirmatory value >0.2 ng/mL.
- EAU emphasizes a confirmed rising PSA after prostatectomy and notes that no single threshold perfectly defines clinically meaningful relapse.
- EAU cites PSA >0.4 ng/mL as the level that best predicts subsequent metastases after prostatectomy in available evidence; this is a prognostic threshold, not a reason to delay salvage treatment.
- Ultrasensitive PSA below 0.2 ng/mL can be useful in high-risk patients but should usually show a confirmed rising trend before treatment is based on it.
- Persistent PSA after prostatectomy—PSA that never becomes undetectable—is distinct from classic delayed BCR.
- After radiation, PSA usually remains measurable because the prostate remains in place.
- PSA can take up to three years or longer to reach its nadir after radiotherapy.
- The Phoenix definition of radiation biochemical recurrence is PSA nadir + 2.0 ng/mL.
- The Phoenix definition also applies when radiation was combined with ADT.
- PSA bounce is a temporary rise followed by a fall and can occur about 1–3 years after radiation; it does not by itself mean the cancer has returned.
- PSA doubling time is a major predictor of recurrence aggressiveness.
- EAU high-risk BCR after prostatectomy includes PSA-DT ≤1 year or pathological Grade Group 4–5.
- EAU high-risk BCR after radiation includes biochemical failure within 18 months or biopsy Grade Group 4–5.
- PSMA PET should be used when the result can affect treatment planning; EAU recommends it after RP when PSA is >0.2 ng/mL and management may change.
- A negative PSMA PET does not exclude microscopic recurrent disease at low PSA.
- AUA/ASTRO/SUO recommends salvage radiation at PSA ≤0.5 ng/mL when it is being considered after prostatectomy.
- Selected high-risk patients may be offered salvage radiation before PSA reaches 0.2 ng/mL.
- Some EAU low-risk BCR patients can reasonably undergo monitoring rather than immediate treatment.
- After radiation, patients considered for local salvage generally require careful localization with PSMA PET and/or MRI and confirmation of local recurrence before high-morbidity salvage treatment.
- The next recurrence page should own local, regional, metastatic and treatment-specific recurrent prostate cancer rather than repeating this PSA definition page.
Clinical bottom line: biochemical recurrence is a PSA-defined warning that prostate cancer may have returned after definitive treatment, not proof that metastatic disease is already present. After prostatectomy, PSA should become undetectable; the AUA standardized definition is PSA ≥0.2 ng/mL with confirmation, although modern salvage decisions may occur at lower PSA in high-risk patients. After radiation, the prostate remains and PSA falls slowly, so the standard Phoenix definition is nadir + 2.0 ng/mL and temporary PSA bounce must be distinguished from true recurrence. The clinical importance of BCR depends on PSA doubling time, grade, stage, interval to recurrence and imaging—not one laboratory value alone. The correct next step is therefore to confirm the trend, classify the recurrence by treatment and risk, use imaging when it will change management, and then decide whether monitoring, local salvage or systemic therapy is appropriate.
Medical disclaimer: This article provides general medical education about biochemical recurrence after prostate cancer treatment. PSA interpretation depends on the original treatment, PSA assay, timing, pathology, prior androgen deprivation, imaging and individual cancer risk. A new or rising PSA should be reviewed by the treating urology, radiation oncology or medical oncology team rather than interpreted from one value in isolation.
For the broader disease framework, return to the Prostate Cancer hub. The previous survivorship bridge covers Libido After Prostate Cancer Treatment. The next contextual page, Recurrent Prostate Cancer, should move beyond the PSA definition into local, regional, distant and treatment-specific recurrence pathways.
Evidence Sources
- European Association of Urology — Prostate Cancer Follow-up, 2026: PSA after prostatectomy and radiation, Phoenix definition, ultrasensitive PSA, surveillance intervals and clinically meaningful recurrence.
- European Association of Urology — Prostate Cancer Treatment, 2026: EAU BCR risk groups, PSMA PET/MRI recommendations and second-line therapy after curative treatment.
- AUA/ASTRO/SUO Salvage Therapy for Prostate Cancer Guideline, 2024: post-prostatectomy BCR definition, ultrasensitive PSA, PSMA PET and salvage-radiation timing.
- AUA/ASTRO/SUO Guideline Part I: treatment decision-making at suspected biochemical recurrence after radical prostatectomy.
- National Cancer Institute — definition of biochemical recurrence/biochemical relapse/PSA failure.
- National Cancer Institute — PSA testing after prostate cancer treatment: repeat testing, trends and recurrence monitoring.
- National Cancer Institute — PSA bounce after prostate radiation: temporary rise followed by fall, typically 1–3 years after treatment.
- National Cancer Institute — Prostate Cancer Treatment PDQ: follow-up after local treatment and biochemical recurrence context.
